Core Viewpoint - The collaboration between 思路迪医药 and 楷拓生物 aims to enhance the development of mRNA-based therapies by leveraging their respective strengths in AI-driven mRNA research and large-scale mRNA production [1] Group 1: Strategic Collaboration - 思路迪医药 has entered into a strategic cooperation framework agreement with 楷拓生物, focusing on the integration of their technologies in mRNA research and delivery systems [1] - The partnership will utilize 思路迪医药's proprietary AI+mRNA research platform and lipid nanoparticle (LNP) delivery system alongside 楷拓生物's expertise in mRNA production [1] Group 2: Technological Advancements - 思路迪医药 has established a globally recognized mRNA technology platform and LNP delivery system, which are crucial for the development of innovative therapies [1] - The mRNA technology platform includes a multi-module tumor vaccine analysis system (3D-PreciseAg) that supports extensive antigen multi-omics analysis and selection of tumor antigens [1] - The AI-enhanced LNP delivery technology platform allows for the screening of thousands of compounds, resulting in the synthesis of various LNP products tailored for different delivery scenarios, improving the efficiency and targeting of mRNA tumor vaccines and immune cell therapies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 3D Medicines Inc. 思路迪医药股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1244） 本公司欣然宣布，思路迪醫藥於2025年8月20日與楷拓生物訂立戰略合作框架協 議（「該協議」）。 根據該協議，雙方將基於思路迪醫藥的自研具有自有知識產權的AI+mRNA研發 平台和脂質體遞送系統(3D-LNP)，與楷拓生物的mRNA規模化生產優勢和經驗， 深化靶向LNP遞送(tLNP)、腫瘤疫苗、in vivo CAR-T/NK等領域的合作。具體實 施將依據後續正式協議落實。此次合作標誌着思路迪醫藥正不斷加速布局mRNA 領域研究，為基於mRNA-LNP技術的創新療法產品後續臨床開發以及未來商業化 提供堅實的產能保障。 思路迪醫藥目前已建立起擁有全球自主知識產權的mRNA技術平台及LNP遞送系 統平台。該mRNA技術平台是基於目前先進的AI技術構建的多模塊腫瘤疫苗分析 平台(3D-Pre ...

Core Viewpoint - Zhonghui Biotech-B (02627.HK) has made a significant debut on the Hong Kong Stock Exchange, with its stock price rising by 158% on the first day, marking the highest first-day gain for a new stock since 2025. The company's market capitalization reached HKD 20.5 billion, ranking fifth among 18 domestic vaccine companies [2][3]. Company Overview - Zhonghui Biotech is a relatively new player in the vaccine industry, having been established only 10 years ago and currently offering just one vaccine on the market, which has been available for less than two years [2]. - The founder, An Youcai, transitioned into the vaccine sector from a non-biological background, emphasizing a commitment to maintaining pricing integrity for its flu vaccine amidst market competition [2][4]. IPO and Financials - The company raised approximately HKD 383 million from its IPO, which will help alleviate its financial pressures, especially considering it had only HKD 115 million in cash at the end of Q1 2025 and needed to repay around HKD 400 million in bank loans within a year [3]. Product and Market Position - Zhonghui Biotech's flu vaccine is the only quadrivalent subunit flu vaccine available in the domestic market, priced at HKD 319 per dose, making it the most expensive flu vaccine in China [8]. - The company has chosen not to participate in the recent price cuts initiated by competitors, focusing instead on a market segment that prioritizes safety and high-quality vaccines [8]. - The flu vaccine generated sales of approximately HKD 259 million in 2024, and the company plans to expand its production capacity from 2 million doses to between 10 million and 15 million doses as it enters international markets [8][9]. Research and Development - Zhonghui Biotech has a pipeline of 11 vaccines, with 10 currently in development. The company is also working on a human diploid rabies vaccine, which is expected to have fewer adverse reactions compared to traditional vaccines [9]. - The company aims to differentiate its products through unique positioning and targeting specific consumer groups, with plans to develop vaccines that can compete with imported products and lead in global technology [10].

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $47.4 million, down from $69.4 million in Q2 2024. Excluding high volume Clean Cap, base revenue increased by 5% year-over-year [19][20] - GAAP net loss before non-controlling interests was $69.8 million for Q2 2025, compared to a loss of $18.4 million in Q2 2024 [20] - Adjusted EBITDA was negative $10.4 million for Q2 2025, down from a positive $13 million in Q2 2024 [21] - Basic and diluted EPS for Q2 2025 was a loss of $0.27 per share, compared to a loss of $0.07 per share in Q2 2024 [21] Business Line Data and Key Metrics Changes - Nucleic Acid Production (NAP) segment revenue was $31.1 million in Q2 2025, with base NAP business excluding high volume Clean Cap up 3% year-over-year [23] - Biologics Safety Testing (BST) segment revenue was $16.3 million in Q2 2025, reflecting a 10% year-over-year increase [24] - Adjusted EBITDA for BST was $10.9 million, resulting in an adjusted EBITDA margin of 67% [24] Market Data and Key Metrics Changes - Revenue by customer type in Q2 2025: 28% biopharma, 30% life sciences and diagnostics, 8% academia, 7% CRO, CMO, CDMO, and 27% to distributors [19] - Revenue by geography: 65% North America, 18% EMEA, 12% Asia Pacific (excluding China), and 5% in China [19] Company Strategy and Development Direction - The company is committed to improving operational excellence and execution through a restructuring plan aimed at reducing annualized expenses by over $15 million [6][7] - Focus on revenue diversification and growth across business segments, particularly in BST and NAP, with investments in new analytical products [10][11] - The company aims to return to sustainable positive adjusted EBITDA and free cash flow by 2026 [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the need for a stronger culture of accountability and operational discipline to drive results [5] - The CEO expressed optimism about the company's future, emphasizing the potential for growth and profitability despite current challenges [15] - The leadership team is focused on stabilizing the organization and exploring further growth opportunities post-restructuring [111] Other Important Information - The company has initiated a comprehensive business review and has withdrawn prior guidance for 2025, planning to reinstate guidance after completing the review [27] - Anticipated restructuring charges of approximately $8 million to $9 million in 2025, primarily for employee severance and related expenses [26] Q&A Session Summary Question: Guidance philosophy and visibility for 2026 targets - Management is focused on controlling costs and gaining confidence in the numbers shared, with no specific red flags indicating incorrect guidance [36][40] Question: Durability of BST improvement and pull forward dynamics - BST showed strong growth, with no significant pull forward dynamics from China or Asia impacting Q2 results [41][43] Question: Growth potential in China - Management expects China to become a growth driver as relations between the U.S. and China improve [47] Question: Impact of tariffs on CDMO business - Currently, there has been little movement regarding tariffs, but potential opportunities exist if tariffs lead to U.S. production shifts [51] Question: Positive surprises and challenges in the business review - Management was surprised by the extent of expenditures and the loyalty of customers in the preclinical to phase three segments [56][58] Question: E-commerce revenue potential - E-commerce currently represents a small percentage of revenue, but management sees significant potential for growth in this area [75][78] Question: Long-term margin potential - Management aims to restore profitability and free cash flow before addressing long-term margin targets [92][94]

Core Insights - The high cost of advanced cell therapy drugs, reaching hundreds of thousands to millions per injection, can potentially be reduced through mRNA and advanced delivery technologies, transforming highly personalized therapies into more universal drugs [1] - The development of in vivo CAR-T therapy pipelines by Chinese biopharmaceutical companies aims to address the long development cycles and high treatment costs associated with traditional CAR-T therapies [1] Company Developments - DeepXing Biotechnology, led by Dr. Linxian Li, has innovated a delivery technology platform using lipid nanoparticles (LNP), enabling "instant modification and treatment," which could significantly lower costs and expand the range of applicable conditions for advanced immunotherapy [2] - The company has rapidly grown into an international team of over 150 people and has secured over 1 billion in financing since its establishment in late 2019 [2] Government Support - Shenzhen has initiated the 2023 second batch of special funds for strategic emerging industries, with DeepXing's LNP delivery technology platform project successfully receiving government investment [3] - The company has also received funding approval for its "R&D Investment Support Plan for Technology-based Enterprises" from the Shenzhen government [3] - DeepXing has four mRNA rare disease therapies that have received pediatric rare disease designation and orphan drug designation from the FDA [3]

Group 1: Domestic News - The State Council announced that from the autumn semester of 2025, public kindergarten tuition fees for large classes will be waived, benefiting approximately 12 million children and reducing family burdens by 20 billion yuan [2] - China's total import and export value of goods reached 25.7 trillion yuan in the first seven months of this year, a year-on-year increase of 3.5%, marking a historical high for the same period [2] - The Ministry of Commerce extended the investigation period for import beef safeguard measures until November 26, 2025, urging related enterprises to monitor developments closely [2] Group 2: Financial Markets - Childcare concept stocks surged, with Chuangyuan Co. rising by 15.34% and others like BeiYinMei and WeiSi Medical increasing over 5%, reflecting strong investor interest in the maternal and infant consumption chain [3] - The Hong Kong Stock Exchange reported a significant year-on-year increase in market capitalization, reaching 44.9 trillion HKD, a 44% rise, with operating income and net profit growing by 16.05% and 5.74% respectively [3] - U.S. stock markets closed higher, with the Dow Jones up 0.19%, Nasdaq up 1.21%, and S&P 500 up 0.73%, driven by a 5.09% jump in Apple’s stock [3] Group 3: Corporate Dynamics - OpenAI launched the revolutionary GPT-5 model, claiming a significant step towards AGI, with a record coding accuracy of 74.9% and a low misinformation rate of 1.6% in health-related areas [4] - Tesla's sales in Europe declined significantly in July, losing its top sales position to Volkswagen, although it saw growth in Spain and Norway [4] - The U.S. government canceled a $500 million mRNA vaccine development project, withdrawing 22 related contracts, which faced criticism from infectious disease experts [4]

NBC还称，目前美国很多科学家和传染病学专家都在反对肯尼迪的做法，因为mRNA技术在新冠疫苗研 发中展现出了相当光明的前景——特别是这一技术路径可以让疫苗快速实现自我更新，以应对一些病毒 多变的毒株。美国的一些流感病毒疫苗目前就正在这一技术路径上进行着重要的探索。因此，有反对肯 尼迪的人就表示，不能因为疫情过去了就把项目砍了，这就好比因为火灾扑灭了，所以就把消防局撤 了。 环球时报消息，据多家美国媒体报道，美国卫生与公众服务部部长罗伯特·F·肯尼迪于当地时间8月5日 宣布，美国政府将砍掉22个与美国高校等机构开展的mRNA疫苗研发合作项目，这些项目总价值近5亿 美元。 但美国国内的反对者认为，这不仅将重创曾在新冠疫情期间助力美国走出疫情的朝阳科研领域，还将让 美国人在下次公共卫生危机袭来时，失去必要的防护。 美国全国广播公司（NBC）就在其报道的大标题中写道，肯尼迪的做法对美国mRNA疫苗这一充满前景 的科研领域是一记重击。 此外，NBC还在报道中着重介绍了肯尼迪以往"反疫苗"言论，比如他曾将新冠病毒疫苗称作"最致命疫 苗"的言论。这家美国媒体认为，肯尼迪如今砍掉mRNA疫苗的合作项目，说明他正在美国卫生与公 ...

Group 1 - U.S. stock index futures are showing positive movement, with Dow futures up 0.29%, S&P 500 futures up 0.23%, and Nasdaq futures up 0.36% [1] - Chinese concept stocks are mixed in pre-market trading, with Alibaba up 1.53%, Pinduoduo up 1.07%, JD down 0.03%, Baidu up 0.87%, and Li Auto down 3.09% [2] - Uber's stock is down 0.17% in pre-market trading ahead of its Q2 earnings report scheduled for release [3] - AMD's stock is down over 5% in pre-market trading after reporting Q2 revenue that exceeded expectations but a significant drop in operating profit margin to 12% from 22% year-over-year, with adjusted net income down 31% to $781 million [4] - Advanced Micro Devices (AMD) reported a revenue increase but a decline in profitability, leading to a pre-market drop [4] Group 2 - Tesla is training a new Full Self-Driving (FSD) model, which is expected to have parameters ten times larger than the current version, with a potential public release by the end of next month [5] - Supermicro's stock is down over 16% in pre-market trading after significantly lowering its revenue guidance for the next quarter to between $6 billion and $7 billion, and reducing its fiscal 2026 revenue forecast by 17.5% to $33 billion [4] - Novo Nordisk reported a 67% year-over-year increase in sales for its weight loss drug Wegovy, reaching 19.53 billion Danish kroner in Q2 [6] - The U.S. Department of Health has withdrawn approximately $500 million in funding for mRNA vaccine development, affecting major vaccine manufacturers like Pfizer, Moderna, and Sanofi, with their stocks showing slight declines [7] - Disney has announced a significant deal involving ESPN and the NFL, exchanging equity and content rights to strengthen ties with a highly valuable sports IP, resulting in a 1.15% drop in Disney's stock [8]

Group 1 - Major stock index futures are showing positive trends, with Dow futures up 0.29%, S&P 500 futures up 0.23%, and Nasdaq futures up 0.06% [1] - Chinese concept stocks are mixed in pre-market trading, with Alibaba up 1.53%, Pinduoduo up 1.07%, JD down 0.03%, Baidu up 0.87%, and Li Auto down 3.09% [1] - Uber's stock is up 2.3% in pre-market trading ahead of its Q2 earnings report scheduled for release before market open on Wednesday [1] Group 2 - AMD's stock is down over 6% in pre-market trading after reporting Q2 revenue that exceeded expectations but a significant drop in operating profit margin to 12% from 22% year-over-year, with adjusted net income of $781 million, down 31% year-over-year [1] - Advanced Micro Devices (AMD) has lowered its revenue guidance for the next quarter to between $6 billion and $7 billion, with adjusted earnings per share expected between $0.40 and $0.52. The revenue forecast for fiscal year 2026 has been reduced from $40 billion to $33 billion, a decrease of 17.5% [2] - Novo Nordisk's weight loss drug Wegovy saw a 67% increase in Q2 sales, reaching 19.53 billion Danish kroner [2] Group 3 - The U.S. Department of Health has withdrawn approximately $500 million in funding for mRNA vaccine development, affecting major vaccine manufacturers including Pfizer, Moderna, and Sanofi, with Pfizer down 0.3%, Moderna down 0.3%, and Sanofi down 0.4% [2] - Disney has made a significant move by exchanging equity in ESPN for core assets from the NFL, establishing a deep partnership with one of the most commercially valuable sports IPs in the U.S., resulting in a 3.3% increase in Disney's stock [3]

Core Viewpoint - The U.S. government has decided to cancel approximately $500 million in funding for mRNA vaccine development, marking a significant shift away from mRNA technology in public health strategy [2][3]. Group 1: Decision Details - U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced the cancellation of the mRNA vaccine development project, which includes the termination of 22 contracts related to mRNA technology by the Biomedical Advanced Research and Development Authority (BARDA) [2][3]. - The decision is influenced by consultations with top experts from the National Institutes of Health (NIH) and the FDA, concluding that the risks of mRNA technology outweigh its benefits for respiratory viruses like COVID-19 and influenza [3][4]. - The U.S. Department of Health and Human Services plans to redirect the canceled funds to "safer and broader vaccine platforms" that remain effective even with viral mutations [3]. Group 2: Expert Opinions - Many experts argue that mRNA vaccines have a significant advantage in rapid development and adaptability, which is crucial for responding to emerging viruses and variants [6]. - Dr. Peter Hotez criticized the decision as undermining national biosecurity and promoting a "pseudo-scientific agenda" [6]. - Dr. Paul Offit expressed concern that the decision was made without scientific evidence, potentially exposing the nation to unnecessary risks [6]. Group 3: Industry Impact - The cancellation of contracts with companies like Moderna and others indicates a broader shift in the U.S. government's approach to vaccine development, which may affect future innovations in the biomedical field [5][6]. - The U.S. Department of Health and Human Services is also terminating contracts with Emory University and Tiba Biotech, which were working on mRNA-based antiviral platforms [6].